Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma.

In murine models, transgenic chemokine-cytokine tumor vaccines overcome many of the limitations of single-agent immunotherapy by producing the sequence of T-cell attraction followed by proliferation. The safety and immunologic effects of this approach in humans were tested in 21 patients with relapsed or refractory neuroblastoma. They received up to 8 subcutaneous injections of a vaccine combining lymphotactin (Lptn)- and interleukin-2 (IL-2)-secreting allogeneic neuroblastoma cells in a dose-escalating scheme. Severe adverse reactions were limited to reversible panniculitis in 5 patients and bone pain in 1 patient. Injection-site biopsies revealed increased cellularity caused by infiltration of CD4+ and CD8+ lymphocytes, eosinophils, and Langerhans cells. Systemically, the vaccine produced a 2-fold (P =.035) expansion of CD4+ T cells, a 3.5-fold (P =.039) expansion of natural killer (NK) cells, a 2.1-fold (P =.014) expansion of eosinophils, and a 1.6-fold (P =.049) increase in serum IL-5. When restimulated in vitro by the immunizing cell line, T cells collected after vaccination showed a 2.3-fold increase (P =.02) of T-helper (TH2)-type CD3+IL-4+ cells. Supernatant collected from restimulated cells showed increased amounts of IL-4 (11.4-fold; P =.021) and IL-5 (8.7-fold; P =.002). Six patients had significant increases in NK cytolytic activity. Fifteen patients made immunoglobulin G (IgG) antibodies that bound to the immunizing cell line. Measurable tumor responses included complete remission in 2 patients and partial response in 1 patient. Hence, allogeneic tumor cell vaccines combining transgenic Lptn with IL-2 appear to have little toxicity in humans and can induce an antitumor immune response.

[1]  A. Zlotnik,et al.  Lymphotactin. , 2020, Clinical immunology and immunopathology.

[2]  H. Hamada,et al.  Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100 , 2002, Gene Therapy.

[3]  J. Xiang,et al.  Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression. , 2002, Cancer research.

[4]  J. Xiang,et al.  Lymphotactin Expression by Engineered Myeloma Cells Drives Tumor Regression: Mediation by CD4+ and CD8+ T Cells and Neutrophils Expressing XCR1 Receptor1 , 2001, The Journal of Immunology.

[5]  D. Olive,et al.  The C-class chemokine, lymphotactin, impairs the induction of Th1-type lymphokines in human CD4(+) T cells. , 2000, Blood.

[6]  H. Hamada,et al.  Adenovirus-mediated lymphotactin gene transfer improves therapeutic efficacy of cytosine deaminase suicide gene therapy in established murine colon carcinoma , 2000, Gene Therapy.

[7]  B. Kushner,et al.  Oral etoposide for refractory and relapsed neuroblastoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  T. Eberlein,et al.  Local secretion of IFN-gamma induces an antitumor response: comparison between T cells plus IL-2 and IFN-gamma transfected tumor cells. , 1999, Journal of immunotherapy.

[9]  F. Graham,et al.  Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. , 1999, Human gene therapy.

[10]  T. Blankenstein,et al.  T Helper Cell Type 1–associated and Cytotoxic T Lymphocyte–mediated Tumor Immunity Is Impaired in Interleukin 4–deficient Mice , 1999, The Journal of experimental medicine.

[11]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[12]  M. Mastrangelo,et al.  Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer , 1998, Cancer Immunology, Immunotherapy.

[13]  D. Campana,et al.  Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. , 1998, Human gene therapy.

[14]  A. Zlotnik,et al.  Molecule of the MonthLymphotactin , 1998 .

[15]  E. Jaffee,et al.  Cancer Vaccines , 1997, Current protocols in human genetics.

[16]  Mantovani Alberto,et al.  Migratory response of human natural killer cells to lymphotactin , 1996, European journal of immunology.

[17]  S. Burdach,et al.  Combined chemokine and cytokine gene transfer enhances antitumor immunity , 1996, Nature Medicine.

[18]  H. Wakimoto,et al.  Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. , 1996, Cancer research.

[19]  T. Schall,et al.  Molecular cloning and functional characterization of human lymphotactin. , 1995, Journal of immunology.

[20]  N. Cheung,et al.  GD2 oligosaccharide: target for cytotoxic T lymphocytes , 1995, The Journal of experimental medicine.

[21]  F. Marshall,et al.  Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials. , 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[22]  G. Maass,et al.  Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[23]  D. Largaespada,et al.  Lymphotactin: a cytokine that represents a new class of chemokine. , 1994, Science.

[24]  S. Rosenberg,et al.  Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest , 1994, Cancer Immunology, Immunotherapy.

[25]  J. Mulé,et al.  Experimental and clinical studies of cytokine gene-modified tumor cells. , 1994, Human gene therapy.

[26]  M. Colombo,et al.  In vitro anti‐tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5 , 1993, International journal of cancer.

[27]  T. Blankenstein,et al.  Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[28]  P. Leder,et al.  An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. , 1992, Science.

[29]  E. Goillot,et al.  Expression of leucocyte adhesion molecules on 66 clinical neuroblastoma specimens , 1991, International journal of cancer.

[30]  W. Paul,et al.  Interleukin-4 : A Prototypic Immunoregulatory Lymphokine , 2003 .

[31]  N. Cheung,et al.  Immunotherapy. Neuroblastoma as a model. , 1991, Pediatric clinics of North America.

[32]  R. R. Robinson,et al.  Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. , 1990, Cancer research.

[33]  S. Miyatake,et al.  Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[34]  M. Macey,et al.  Enhancement of monoclonal antibody dependent cell mediated cytotoxicity by IL2 and GM‐CSF , 1989, British journal of haematology.

[35]  R. Kennett,et al.  The effects of gamma interferon on the natural killer and tumor cells of children with neuroblastoma. A preliminary report , 1989, Cancer.

[36]  D. Monos,et al.  IFN-treated neuroblastoma cell lines remain resistant to T cell-mediated allo-killing, and susceptible to non-MHC-restricted cytotoxicity. , 1988, Journal of immunology.

[37]  D. Wilson,et al.  Human neuroblastoma cell lines are susceptible to lysis by natural killer cells but not by cytotoxic T lymphocytes. , 1985, Journal of immunology.

[38]  L. Qi,et al.  Immunologic Targets for the Gene Therapy of Cancer , 2002 .

[39]  A. Nagler,et al.  Eosinophils activation in post-autologous bone marrow transplanted patients treated with subcutaneous interleukin-2 and interferon-alpha 2A immunotherapy. , 1994, Leukemia.

[40]  M. Colombo,et al.  Erratum: In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5 (Int. J. Cancer, 54, 8-15 (1993)) , 1993 .